NARA Discovery
Article Details
← Back to Search Results
Journal Article

Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication

Hideaki Tani; Iska Moxon-Emre; Natalie J. Forde; Nicholas H. Neufeld; Kathleen S. Bingham; Ellen M. Whyte; Barnett S. Meyers; George S. Alexopoulos; Matthew J. Hoptman; Anthony J. Rothschild; Hiroyuki Uchida; Alastair J. Flint; Benoit H. Mulsant; Aristotle N. Voineskos
Brain Imaging and Behavior · Vol. 18, Issue 1 · pp. 117-129 · 2023

Abstract

Background The neurobiology of psychotic depression is not well understood and can be confounded by antipsychotics. Magnetic resonance spectroscopy (MRS) is an ideal tool to measure brain metabolites non-invasively. We cross-sectionally assessed brain metabolites in patients with remitted psychotic depression and controls. We also longitudinally assessed the effects of olanzapine versus placebo on brain metabolites. Methods Following remission, patients with psychotic depression were randomized to continue sertraline + olanzapine ( n = 15) or switched to sertraline + placebo ( n = 18), at which point they completed an MRS scan. Patients completed a second scan either 36 weeks later, relapse, or discontinuation. Where water-scaled metabolite levels were obtained and a Point-RESolved Spectroscopy sequence was utilized, choline, myo-inositol, glutamate + glutamine (Glx), N -acetylaspartate, and creatine were measured in the left dorsolateral prefrontal cortex (L-DLPFC) and dorsal anterior cingulate cortex (dACC). An ANCOVA was used to compare metabolites between patients ( n = 40) and controls ( n = 46). A linear mixed-model was used to compare olanzapine versus placebo groups. Results Cross-sectionally, patients (compared to controls) had higher myo-inositol (standardized mean difference [SMD] = 0.84; 95%CI = 0.25–1.44; p = 0.005) in the dACC but not different Glx, choline, N -acetylaspartate, and creatine. Longitudinally, patients randomized to placebo (compared to olanzapine) showed a significantly greater change with a reduction of creatine (SMD = 1.51; 95%CI = 0.71–2.31; p = 0.0002) in the dACC but not glutamate + glutamine, choline, myo-inositol, and N -acetylaspartate. Conclusions Patients with remitted psychotic depression have higher myo-inositol than controls. Olanzapine may maintain creatine levels. Future studies are needed to further disentangle the mechanisms of action of olanzapine.

Bibliographic Information

JournalBrain Imaging and Behavior
PublisherSpringer
Publication Date2023-11-02
Publication Year2023
Volume18
Issue1
Pages117-129
Document TypeJournal Article
eISSN1931-7565
DOI10.1007/s11682-023-00807-0

Access Information

NARA Access Coverage2007-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11682
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.